aTyr Pharma Announces Findings From Interim Analysis Of Eight Patients In Ongoing Phase 2 EFZO-CONNECT Study Evaluating Efzofitimod In SSc-ILD Patients

aTyr Pharma +6.72% Pre

aTyr Pharma

ATYR

0.78

0.78

+6.72%

0.00% Pre

Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks.

Efzofitimod was generally safe and well tolerated at all doses.

SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced findings from an interim analysis of eight patients in the ongoing Phase 2 EFZO-CONNECT™ study evaluating its lead therapeutic candidate, efzofitimod, in patients with limited or diffuse systemic sclerosis (SSc, or scleroderma)-related interstitial lung disease (ILD).

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.